The Consultant's Mirage: Why Standard Advice Fails a Dental QoE Audit

The fastest way to get slaughtered in a Quality of Earnings audit is to follow the advice of a traditional dental consultant.

For years, the playbook for selling a dental practice has been written by people who do not actually understand how institutional buyers value them. Well-meaning consultants, advisors, and industry gurus have told dentists that if they want to command a premium multiple, they just need to do two things: boost top-line production and cut overhead.

It sounds like common sense. It is exactly what you would do if you were preparing to sell a retail asset to another individual dentist. So, practice owners do what they are told. They follow the playbook. They work on their team culture. They invest in soft skills training. They bring in communication coaches and leadership workshops.

And look — I actually believe in soft skills. A well-led team with strong culture is a real asset. But most soft skills consultants are not working with clinical data. They are working with people, process, and communication. That is genuinely valuable work. It is just not the work that determines your valuation.

To be fair, most dental consultants are not saboteurs. They fall into a few recognizable categories: a former hygienist who knows hygiene deeply, a former office manager who knows scheduling and front-desk operations cold, a former clinical director who understands team dynamics and culture. These are real competencies and these people are genuinely good at what they know.

The problem is that what they know is a fraction of what determines your valuation. And when they step outside their lane — when the hygiene consultant starts advising on case acceptance strategy, or the soft skills coach starts talking about EBITDA optimization, or the operations specialist starts framing your practice for a transaction they have never actually been through — they are smart enough to sound credible and dangerous enough to be wrong in ways that cost you millions.

Here is the hard truth: if those investments do not move the needle on the numbers that matter in a transaction, they are a very expensive way to feel good about a practice that is still completely exposed.

And if you are thinking your analytics platform has this covered — Dental Intel, Jarvis Analytics, Practice by Numbers — it does not. Those are excellent tools for managing the day-to-day operations of your practice. They surface KPIs, track trends, and help you make better decisions in real time. But they are not built to forensically stress-test your clinical baseline the way an institutional buyer will. They do not pull raw procedure-code level data and analyze it the way a QoE team does. They are built to help you run the practice. They are not built to defend it.

Driven by standard consulting playbooks, practices try to bridge the gap using short-term hacks:

• They pack the schedule with a massive influx of new patients, running a high-churn marketing treadmill to mask the fact that their hygiene department is bleeding retention.
• They squeeze their supply costs and delay necessary operational investments to artificially inflate their short-term EBITDA.
• They ignore case acceptance entirely.

Our benchmarking puts the industry average for case acceptance at around 48%. The practices we have worked with that are built to survive institutional scrutiny are operating at 75%. Most practices fall somewhere between 40% and 60%.

That gap is not undiagnosed treatment. The treatment has already been diagnosed and presented. It was prescribed, discussed, and then it walked out the door without being scheduled or collected. That is presented production that never converted — and it represents millions of dollars sitting in the clinical ledger that the practice never captured.

The catch? It is completely invisible to traditional channels:

• It does not show up in the tax returns.
• It does not appear in the broker’s prospectus.
• Traditional due diligence does not take case acceptance into account at all.

The seller never knows it is a problem, and the buyer never knows what they are walking into. They look at the spreadsheet their consultant built for them, and it looks fine. The revenue is up. The margins look acceptable. The multiple looks reasonable.

But it is a complete mirage.

The Institutional Reality Check

Let’s be precise about who this applies to right now. Private Equity is largely not acquiring individual practices anymore unless they are running $3 million or more in collections. The current PE model is focused on acquiring groups — three to fifteen practices or more — where the platform economics justify the diligence cost. A 200-practice platform will acquire a 40-practice group if the geography, demographics, or operational fit makes sense. There is no ceiling on the buy side. (For why that collections threshold quietly decides your entire valuation, see The Boutique Fallacy.)

But here is the question every individual practice owner should be asking: how long before the QoE discipline gets applied to individual transactions?

The answer is that it is already starting. Sophisticated buyers — even individual dentists acquiring with SBA financing — are beginning to demand more forensic clarity before they sign. The tools exist. The data is accessible. And as buyers get smarter and capital gets more expensive, the standard of diligence is going to rise at every level of the market.

The practice that can survive a QoE-style review is a fundamentally better asset regardless of who is buying it. The practice that cannot survive one is exposed — whether the buyer is a PE platform or a dentist writing their first check.

When an institutional QoE team does walk into a practice, they do not care about the consultant’s projections. They do not care about the narrative. They bypass the General Ledger entirely. They plug directly into the practice management software and pull raw, procedure-code level data straight from the clinical engine.

• They spot inflated active patient counts: A practice claiming 2,400 active patients on a prospectus may only have 900 who have actually been seen in the past 18 months. The other 1,500 are dormant. The software counted them. The buyer is not going to pay a premium multiple on a patient base that does not exist.
• They flag provider dependencies: For an individual practice sale, provider concentration is a legitimate risk — if the selling doctor generates the majority of production and then leaves, that practice has a real problem. In a group acquisition of 14 practices, the departure of one provider does not clinically affect the other 13. PE underwrites the platform, not the individual. The risk calculus is completely different depending on what is actually being sold.
• They identify the true case acceptance conversion gap: The presented treatment that was never scheduled and never collected.

And they will use all of that data to systematically dismantle the valuation.

The Cost of Phantom EBITDA

The inflated numbers the consultant helped build created what we call Phantom EBITDA. It is margin that exists on paper but cannot survive institutional scrutiny.

When the QoE team exposes Phantom EBITDA, they don’t just politely point it out. They deduct it from the valuation. They use it to force structural management fees before closing. They use it as a weapon to compress the multiple the seller thought was guaranteed.

The seller is left sitting at the negotiating table, watching millions of dollars evaporate, realizing too late that they brought a spreadsheet to a data war.

You cannot fix a clinical data problem with an accounting trick.

If your advisor is taking you to market without normalizing your clinical data at the procedure-code level first, they are not helping you maximize your exit. They are committing financial malpractice. They are sending you into the most important transaction of your life completely exposed.

Know Your Baseline Before They Build It For You

The era of selling a practice on a narrative and a top-line revenue number is over. Institutional buyers are too smart, their data teams are too sophisticated, and capital is too expensive for them to buy a mirage.

If you want to command a premium valuation, you have to build a bulletproof asset. And you cannot build a bulletproof asset by hacking your way to a higher multiple.

You have to know your clinical baseline before the buyer builds it for you.

You have to know your true case acceptance rate. You have to know your unadjusted provider dependency. You have to know exactly what your data looks like when it is pulled raw from the clinical ledger.

Because if you don’t know what the QoE team is going to find, you are already losing the negotiation.

---

About the author — Joe DeLuca is Chief Analytics Officer and co-principal of Precision Dental Analytics, where he builds the benchmarking architecture behind the firm’s M&A defense and growth work. He is the author of The Root of Leadership.